Palo Alto Medical Foundation
We aim at identifying potential biomarkers in plasma indicative of post-acute coronavirus SARS-CoV-2 Syndrome (Long COVID). Our case-control study will compare Long COVID patients to healthy patients from Sutter Health.
Two measures will be obtained from participants' plasma: 1. microbial signatures using Karius' agnostic metagenomic assay via microbial cell-free DNA (mcfDNA) sequencing (kariusdx.com) 2. cytokine signatures using 71-plex and 18-plex assays (evetechnologies.com). The diagnostic utility of the potential biomarkers, including signatures derived from microbial cell-free DNA fragments found in plasma and plasma cytokines, will be evaluated independently and in various combinations to determine whether and to what extent we can accurately identify Long COVID patients. Moreover, we plan to leverag…
Inclusion Criteria: * ≥ 18-year-old * English speaking (per Sutter medical records information) * Ability and willingness to provide signed Consent Form * Ability to comply with the study protocol * Ability to attend the study visit, complete questionnaires, have blood collected and tested And, either Long-COVID or Healthy control as described below * Long-COVID patient Cohort (n=75) * Sutter patient who is a patient from Sutter Health Holistic/Integrative Medicine clinic * Documentation of a long-COVID diagnosis (U09.9) for patient's initial visit in clinic between 01/01/2021 and 06/30/…
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.